Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology firm focused on tumor-selective immuno-oncology therapies, will be presenting at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 8:00 a.m. ET. Dr. Marty Huber, president of research and development and chief medical officer, will lead the presentation. A live webcast will be accessible on the company’s website, with an archived replay available for 30 days.
The company utilizes its proprietary GPS platform to innovate cytokines and biologics aimed at localized anti-tumor activity.
- None.
- None.
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 8:00 a.m. ET.
A live webcast will be available in the Investors and Media section of the Xilio Therapeutics’ website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics’ website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including its clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, as well as its earlier pipeline, including XTX301, a tumor-selective IL-12, and XTX401, a tumor-selective IL-15. For more information, please visit www.xiliotx.com.
For Investor Inquiries:
Chelcie Lister, THRUST Strategic Communications
chelcie@thrustsc.com
For Media Inquiries:
Dan Budwick
dan@1abmedia.com
FAQ
What is the date and time of Xilio Therapeutics' presentation at the Needham Healthcare Conference?
Who will present for Xilio Therapeutics at the Needham Conference?
Where can I watch the Xilio Therapeutics conference presentation live?
How long will the Xilio Therapeutics presentation replay be available?
What is the primary focus of Xilio Therapeutics?
